Javier Sánchez-‐Rubio Fernández & col.
480
30.
Clark L, et al. Ideal vial size for bortezomib: real-‐world data on waste and cost reduction in
treatment of multiple myeloma in Brazil. Value Health. 2011;(5 Suppl 1):S82-‐4.
31.
Agemed. Ficha Técnica Velcade
®
. (acceso agosto 2012).
32.
André P, et al. Stability of bortezomib 1-‐mg/mL solution in plastic syringe and glass vial.
Ann Pharmacother. 2005;39(9):1462-‐6.
33.
Walker SE, et al. Stability of bortezomib reconstituted with 0.9% sodium chloride at 4ºC
and room temperature (23ºC). Cn J Hosp Pharm 2008;61(1):14-‐20.
34.
Bolognese A, et al. An NMR Study of the bortezomib degradation under clinical use
conditions. Adv Hematol. 2009;2009:704928.
35.
Vanderloo JP, et al. Stability of unused reconstituted bortezomib in original manufacturer
vials. J Oncol Pharm Pract. 2011;17(4):400-‐2.
36.
Perissutti M, et al. Etude de la stabilité d'une solution de bortézomib à 1 mg/mL
conditionnée en seringue de polypropylène. Congrès SFPO 2011.
37.
Sánchez-‐Rubio Ferrández J, et al. Extended stability of bortezomib. Hospital Pharmacy
Europe 2010; 49:17-‐8.
38.
De Giorgi I, et al. Sterility validity period of vials after multiple sampling under vertical
laminar airflow hood. J Oncol Pharm Pract. 2005;11(2):57-‐62.
39.
Roy JJ, et al. Study of microbiological safety of 25 oncology drugs after multiple uses in
aseptic conditions. Int J Pharm Compd 2011;15(5):428-‐34.
40.
Holmes CJ, et al. Viability of microorganisms in fluorouracil and cisplatin small-‐volume
injections. Am J Hosp Pharm. 1988; 45:1089-‐91.
41.
Patel K, et al. Microbial inhibitory properties and stability of topotecan hydrochloride
injection. Am J Health Syst Pharm. 1998;55(15):1584-‐7.
42.
Kawamura K. The media fill (simulation) test is the best method to evaluate aseptic
processing. PDA J Pharm Sci Technol 2002;56:57-‐8.
43.
Trissel LA, et al. Using a medium-‐fill simulation to evaluate the microbial contamination
rate for USP medium-‐risk-‐level compounding. Am J Health Syst Pharm 2005;62(3):285-‐8.
44.
Trissel LA, et al. Effect of two work practice changes on the microbial contamination rates
of pharmacy-‐compounded sterile preparations. Am J Health Syst Pharm. 2007;64(8):837-‐
41.
